Last year, drug discovery company Plexxikon made front-page news with its highly successful anti-cancer drug, Zelboraf, a product that was chemically optimized using data from ALS x-rays. Designed to disrupt malignant melanoma, the drug was so successful in human testing that trials were halted so that patients in the trial could all be given Zelboraf. Zelboraf marked a significant advancement for patients with metastatic melanoma who historically have had very limited treatment options.
Read more »